• Contact

  • Newsletter

  • About us

  • Delivery options

  • Prospero Book Market Podcast

  • Immunotherpy in Head and Neck Cancer: DE

    Immunotherpy in Head and Neck Cancer by Saini, Deepika; GUPTA, DS; JAIN, AASHITA;

    DE

      • GET 5% OFF

      • The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
      • Publisher's listprice EUR 79.90
      • The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.

        33 138 Ft (31 560 Ft + 5% VAT)
      • Discount 5% (cc. 1 657 Ft off)
      • Discounted price 31 481 Ft (29 982 Ft + 5% VAT)

    33 138 Ft

    db

    Availability

    printed on demand

    Why don't you give exact delivery time?

    Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.

    Product details:

    • Publisher LAP Lambert Academic Publishing
    • Date of Publication 1 January 2024
    • Number of Volumes Großformatiges Paperback. Klappenbroschur

    • ISBN 9786207474936
    • Binding Paperback
    • No. of pages164 pages
    • Size 220x150 mm
    • Language English
    • 525

    Categories

    Long description:

    Immunotherapy has revolutionized the treatment landscape for head and neck cancer, offering new hope and improved outcomes for patients. This approach harnesses the power of the immune system to target and destroy cancer cells, providing a more targeted and potentially less toxic alternative to traditional treatments like chemotherapy and radiation therapy. Key immunotherapy strategies in head and neck cancer include immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and combination therapies. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, block the inhibitory signals that cancer cells use to evade detection by the immune system, allowing immune cells to recognize and attack the tumor.Adoptive cell therapies, like CAR-T cell therapy, involve engineering a patient's own immune cells to specifically target cancer cells. Cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells, either by using tumor antigens or dendritic cells to boost immune responses. Overall, immunotherapy represents a promising approach for head and neck cancer, offering personalized and targeted treatments that can improve survival rates.

    More